![]() |
|
|
Vol. 304, Issue 1, 102-108, January 2003
Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil (M.L.V., J.B.M., C.A.M., F.A.C.R., R.A.R.); Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Sao Paolo, Brazil (S.H.F., F.Q.C.); and Endocrinology Section, National Institute for Biological Standards and Control, London, United Kingdom (S.P.)
| |
Abstract |
|---|
|
|
|---|
The antinociceptive effects of interleukin (IL)-4, -10, and -13 were
investigated in two different experimental pain models. Our results
showed that pretreatment (30 min) with IL-4 (1-5 ng/animal), IL-10
(0.4-10 ng/animal), or IL-13 (0.4-2.5 ng/animal) inhibited the
writhing response induced by the i.p. administration of acetic acid
(53-89%) or zymosan (63-74%) in mice, and the knee joint incapacitation induced by i.a. injection of zymosan (49-66%) in rats.
Neither of the cytokines affected the pain elicited in mice using the
hot-plate test. This analgesic effect of IL-4, -10, and -13 was not
reversed by the combined pretreatment with the opioid receptor
antagonist naloxone. IL-4, -10, or -13 significantly inhibited the
release of both tumor necrosis factor (TNF)-
(60, 53, and 100%,
respectively) and IL-1
(80, 100, and 100%, respectively) by mice
peritoneal macrophages obtained after local (i.p.) injection of
zymosan. Antisera against IL-4, -10, and -13 potentiated both the
zymosan-induced writhing response and the articular incapacitation. Our
results demonstrate that IL-4, -10, and -13 display analgesic activity
that is probably not due to endogenous opioid release. This analgesic
effect could be related to a peripheral mechanism, probably via the
inhibition of the release of the pro-inflammatory cytokines TNF-
and
IL-1
by resident peritoneal macrophages.
| |
Introduction |
|---|
|
|
|---|
Cytokines
constitute a link between cellular injury and recognition of nonself
and the development of local and systemic signs and symptoms of
inflammation (Dinarello et al., 1986
; Ferreira et al., 1988
; Faccioli
et al., 1990
). In this context, it was shown in a model of mechanical
hyperalgesia that carrageenin-evoked hyperalgesia results from the
combined effects of the release of cyclooxygenase products and
sympathomimetic amines (Nakamura and Ferreira, 1987
). A cascade of
cytokine release preceded the generation of these mediators.
Carrageenin and lipopolysaccharide caused the release of
bradykinin, which stimulated the release of TNF-
. TNF-
induced
the release of IL-1
and -6, which stimulated the production of
cyclooxygenase products and IL-8, which, in turn, stimulated production
of sympathomimetic mediators (Cunha et al., 1991
, 1992a
; Ferreira et
al., 1993
). In a different model, the writhing test in mice, zymosan,
or acetic acid-induced writhing was also mediated by cyclooxygenase
products and sympathomimetic amines, the release of which was mediated
by TNF-
, IL-1
, and IL-8 (Duarte et al., 1988
; Thomazzi et al.,
1997
). These cytokines appear to be released by resident peritoneal
macrophages and mast cells since the depletion of these cells from the
mouse peritoneal cavity abolished the acetic acid- or zymosan-induced
writhing response. Furthermore, the increase in the numbers of these
cells in the peritoneal cavity enhanced the number of writhing
movements induced by both stimuli (Ribeiro et al., 2000
).
Within the last decade, cytokines generally regarded as
anti-inflammatory have been described that inhibit the production of
other cytokines such as IL-1
, -6, -8, and TNF-
, which are generally regarded as proinflammatory. The class of anti-inflammatory cytokines includes IL-4, -10, -13, and transforming growth factor-
(Hart et al., 1989
; Fiorentino et al., 1991
; Cassatella et al., 1993
;
Callard et al., 1996
).
IL-10 is produced by several cell types, including
Th2 lymphocytes, monocytes, macrophages, and mast
cells (Fiorentino et al., 1989
). IL-10 is believed to play a role in
inhibiting delayed-type hypersensitivity reactions (Howard and
O'Garra, 1992
) and in the suppression of macrophage functions such as
class II expression (De Waal Malefyt et al., 1991
), adhesion
(Fiorentino et al., 1991
), the synthesis of proinflammatory cytokines,
and the expression of COX-2 and iNOS (Bogdan et al., 1991
; De Waal
Malefyt et al., 1991
; Fiorentino et al., 1991
; Oswald et al., 1992
;
Cunha et al., 1992b
; Niiro et al., 1995
, 1997
). Recently, it was shown
that IL-10 inhibits the inflammatory mechanical hyperalgesia induced by
carrageenin through two mechanisms: inhibition of hyperalgesic cytokine
release and blockade of COX-2 induction (Poole et al., 1995
).
IL-4 and -13 are produced mainly by Th2
lymphocytes and by mast cells (McKenzie et al., 1993
; Burd et al.,
1995
; De Waal Malefyt et al., 1995
) and share a number of biological
properties, including the inhibition of proinflammatory cytokine
production (Hart et al., 1989
; Callard et al., 1996
; Muchamuel et al.,
1997
) and the induction of COX-2 and of iNOS with a consequent
reduction in the production of prostaglandins and nitric oxide (Seitz
et al., 1994
; Niiro et al., 1995
; Onoe et al., 1996
). Also, IL-4 can
suppress the delayed-type hypersensitivity in experimental animals and in humans (Röcken et al., 1996
), possibly because of its capacity to induce Th2 cell responses. IL-13 may exert an
important role in rheumatoid arthritis since it is present at high
levels in synovial fluid and can inhibit the production of IL-1 and TNF by mononuclear cells (Isomaki et al., 1996
). Recently, it was shown
that IL-4 (probably released by local mast cells) and IL-13 (probably
released by local T lymphocytes) inhibited the mechanical hyperalgesia
induced by carrageenin, bradykinin, and TNF-
(Cunha et al., 1999
;
Lorenzetti et al., 2001
). This antihyperalgesic effect appeared to be
due to inhibition of prostaglandin E and cytokine production.
Given the demonstrated capacity of IL-4, -10, and -13 to inhibit
mechanical hyperalgesia in rats and the production of proinflammatory hyperalgesic cytokines, the present study extended the investigation of
the antinociceptive effect of these molecules, testing their possible
antinociceptive effects in the writhing test in mice (Collier et al.,
1968
), the knee joint incapacitation test in rats (Tonussi and
Ferreira, 1992
), and the hot-plate test in mice (Eddy and Leimbach,
1953
). This last test was used to investigate the possible central
effect of these cytokines. The involvement of opioids in the
antinociceptive effect of these cytokines was also investigated.
| |
Materials and Methods |
|---|
|
|
|---|
Animals
Male Swiss mice weighing 25 to 30 g and male Wistar rats (180-200 g) from the animal colony of the Federal University of Ceará were used for nociceptive tests. The animals received water and food ad libitum. The ethical guidelines in the NIH Guide for Care and Use of Laboratory Animals were followed throughout the experiments described.
Nociceptive Tests
Writhing Test.
The writhing test is described in detail
elsewhere (Collier et al., 1968
). Zymosan or acetic acid were injected
into the peritoneal cavities of mice, which were placed in a large
glass cylinder, and the intensity of nociception was quantified by
counting the total number of writhings occurring between 0 and 30 min
after stimulus injection. The writhing response consists of a
contraction of the abdominal muscles together with a stretching of the
hind limbs. The doses of the nociceptive stimuli were: zymosan (1 mg/0.2 ml/mouse) and acetic acid (0.1 ml/10 g body weight of a 0.6%
v/v solution).
Rat Knee Joint Incapacitation Test.
The rat knee joint
incapacitation test is described in detail elsewhere (Tonussi and
Ferreira, 1992
; Rocha et al., 1999
). In this test, a computer-assisted
device measures the length of time that a specific hind paw fails to
touch the surface of a rotating cylinder in a 1-min period (paw
elevation time). In normal animals, paw elevation time is approximately
10 to 15 s. In our experiments, incapacitation was studied in
animals injected with zymosan (1 mg/animal) into the knee joint, and
the period for which the hind paw failed to touch the rotating cylinder
was interpreted as being proportional to the pain felt by the animal.
Paw elevation time was measured before zymosan administration (control
time, T0) and, thereafter, every hour
for 4 h (T1,
T2,
T3, and
T4). The results were expressed as
paw elevation time [T(1-4)
T0].
Hot-Plate Test.
Reaction times were measured by the
low-temperature (51.5 ± 2°C) hot-plate method described by Eddy
and Leimbach (1953)
. Each mouse was subjected to two trials on the hot
plate separated by a 30-min interval. The first trial was used for
habituation of the animals with the test procedure. The second trial
served to obtain the control reaction time (licking of the hind feet or jumping) for each animal. Male Swiss mice were preselected, and animal
showing a reaction time greater than 10 s were discarded. The
reaction time for each mouse was determined on the hot-plate surface
before and 30, 60, and 90 min after drug administration. To avoid
injuries, the animals were never left more than 40 s on the hot plate.
Production of TNF-
and IL-1
by Cells Harvested from
Peritoneal Cavities Stimulated with Zymosan
Saline (0.2 ml) or zymosan (1 mg/0.2 ml) was injected i.p. in
the mice. After 15 min, the peritoneal cavities were washed with saline
(1 ml/cavity), and the exudates were centrifuged at 300 g for 10 min. Pelleted cells were resuspended in 500 µl of RPMI 1640 medium
supplemented with 10% fetal calf serum; cells were then counted, and
5 × 105 cells were plated onto 48-well
plastic tissue culture plates. The concentrations of TNF-
and
IL-1
in the supernatants after 12 h of culture were determined
by an enzyme-linked immunosorbent assay, as described previously (Cunha
et al., 1999
). Briefly, microtiter plates were coated overnight at
4°C with an antibody against murine TNF-
or IL-1
(10 µg/ml).
After blocking the plates, the samples and standards at various
dilutions were added in duplicate and incubated at 4°C for 24 h.
The plates were washed three times with buffer, and a second
biotinylated polyclonal antibody against TNF-
or IL-1
(diluted
1/1000; 100 µl/well) was added. After a further incubation at room
temperature for 1 h, the plates were washed, and 100 µl of
avidin-horseradish peroxidase, diluted 1:5000, was added.
O-Phenylenediamine color reagent (100 µl) was added 15 min later, and the plates were incubated in the dark at 37°C for
15 to 20 min. The enzyme reaction was stopped with
H2SO4, and the absorbency
at 490 nM was measured. Results are reported as means ± S.E.M. of
three animals.
Experimental Protocols
Effect of Pretreatment with IL-4, -10, and -13 on the Writhing Response Induced by Acetic Acid or Zymosan. Mice were treated i.p. with murine IL-4 (1-5 ng/cavity), IL-10 (0.4-10 ng/cavity), or human IL-13 (0.4-2.5 ng/cavity), and after 30 min, zymosan (1 mg/0.2 ml/mouse) or 0.1 ml/10 g body weight of acetic acid solution at concentration of 0.6% (v/v) was injected i.p. The number of writhes was counted as described above.
Effect of Pretreatment with IL-4, -10, and -13 on the Rat Knee Joint Incapacitation Induced by Zymosan. Rats were treated i.p. with human IL-4 (1-5 ng/cavity), IL-10 (2-10 ng/cavity), or IL-13 (1-2.5 ng/cavity), and after 30 min, zymosan (1 mg/joint) was injected i.a. in a volume of 50 µl. Incapacitation was measured as described above.
Effect of IL-4, -10, and -13 in the Hot-Plate Test. Immediately after determination of control reaction time (see above), groups of six mice were treated i.p. with saline, IL-4 (5 ng/cavity), IL-10 (10 ng/cavity), IL-13 (2.5 ng/cavity), morphine (5 mg/kg), or indomethacin (2 mg/kg) in a volume of 0.2 ml. The reaction time was measured 30, 60, and 90 min after the treatment.
Effect of Pretreatment with Naloxone upon the Antinociceptive Activity of IL-4, -10, and -13 in Acetic Acid-Induced Writhings in Mice. Mice were pretreated s.c. with saline or naloxone (2 mg/kg). Fifteen minutes later they were injected i.p. with saline, murine IL-4 (5 ng/cavity), murine IL-10 (10 ng/cavity), human IL-13 (2.5 ng/cavity), or morphine (5 mg/kg). Thirty minutes after, acetic acid (0.1 ml/10 g body weight of a 0.6% v/v solution) was injected i.p., and the number of writhings was determined as described above.
Effect of IL-4, -10, and -13 Pretreatment upon TNF-
and
IL-1
Production by Peritoneal Cells Harvested from Cavities
Stimulated with Zymosan.
Mice were pretreated i.p. with murine
IL-4 (5 ng/cavity), murine IL-10 (10 ng/cavity), or human IL-13 (2.5 ng/cavity) 30 min before the i.p. administration of zymosan (1 mg/cavity). The control group received only saline (S) (0.2 ml) and a
nontreated (NT) group received saline before the zymosan. After 15 min,
total resident peritoneal cells were harvested with RPMI 1640 culture medium, plated (5 × 105 cells/well) and
incubated in a CO2 incubator. TNF-
and IL-1
levels were measured in the supernatants after 12 h of culture.
Effect of Antisera against Interleukin-4, -10, and -13 upon the Nociceptive Activity of Zymosan in the Writhing Test. Fifty microliters of antiserum against murine interleukin-4, -10, or -13, or of a control (preimmune) serum were diluted in 250 µl of saline and then injected into the peritoneal cavities of mice; 15 min later, animals received an i.p. injection of zymosan (500 µg/0.2 ml/mouse). The writhings were counted as described above.
Effect of Antisera against Interleukin-4, -10, and 13 upon the Nociceptive Activity of Zymosan in the Rat Knee Joint Incapacitation Test. Fifty microliters of antiserum against rat interleukin-4, -10, or -13, or of a control (preimmune) serum were injected into the rat right knee joint cavity; 15 min later, zymosan (500 µg/25 µl/cavity) was injected into the same articular cavity. Articular incapacitation was measured as described above.
Compounds
The following materials were obtained from the sources
indicated: zymosan A (Sigma-Aldrich, St. Louis, MO), glacial acetic acid (Merck, São Paulo, Brazil), indomethacin (Merck,
Sharp and Dohme-MSD, São Paulo, Brazil), morphine
(Cristalia-Brazil, São Paulo, Brazil), naloxone (Rhodia Farma,
São Paulo, Brazil). Recombinant human and murine IL-4, human and
murine IL-10, and human IL-13 [National Institute for Biological
Standards and Control (NIBSC) preparations coded: 88/656, 92/516, and
94/662]. The specific activities of these materials are: IL-4, 1000 IU
100 ng
1 ampoule
1;
IL-10, 5000 IU 1 µg
1
ampoule
1; and IL-13, 1000 IU 1 mg
1 ampoule
1. Zymosan,
morphine, naloxone, and the cytokines used were all diluted in a 0.9%
NaCl solution. Indomethacin was diluted in a 5%
NaHCO3 solution, and pH was adjusted to 8.0 using
0.1 N HCl. Glacial acetic acid was diluted in deionized water. Sheep
anti-murine or anti-rat IL-4, -10, and -13 sera, and preimmune serum
were NIBSC preparations.
Data Analysis
Results are presented as means ± S.E.M. of measurements made on at least six animals in each group. Differences between responses were evaluated by analysis of variance followed by Tukey's test. Statistical differences were considered to be significant at p < 0.05.
| |
Results |
|---|
|
|
|---|
Effect of Pretreatment with IL-4, -10, and -13 on the Writhing
Response to Acetic Acid or Zymosan.
The intraperitoneal injection
in mice of 0.1 ml/10 g body weight of a 0.6% (v/v) solution of acetic
acid or zymosan (1 mg/mouse) induced a writhing response between 0 and
30 min later. IL-4 (1-5 ng/cavity), IL-10 (0.4-10 ng/cavity), or
IL-13 (0.4-2.5 ng/cavity) injected i.p. 30 min before either of the
stimuli significantly inhibited the nociceptive response
(p < 0.001) with 59, 53, and 89% of inhibition on
average for the different doses when the stimulus was acetic acid (Fig.
1A) and 63, 74, and 62% on average for
the different doses when the stimulus was zymosan (Zym) (Fig. 1B), for
IL-4, -10, and -13, respectively.
|
Effect of Pretreatment with IL-4, -10, and -13 on the Rat Knee
Joint Incapacitation Induced by Zymosan.
The intra-articular
injection of zymosan (1 mg/cavity) induced articular incapacitation,
which was maximal in the 3rd and 4th h after stimulus injection. IL-4
at a dose of 5 ng/cavity, but not at a dose of 1 ng/cavity,
significantly inhibited the zymosan-evoked nociception in the 3rd h by
49% (p < 0.01; Fig. 2A). IL-10 (2 and 10 ng/cavity) blocked
the nociceptive effect in the 3rd and 4th h by 65 and 66%
(p < 0.01), respectively (Fig. 2B). IL-13 (1 and 2.5 ng/cavity) inhibited the nociceptive response in the 3rd h by 57%
(p < 0.05), but only the dose of 1 ng/cavity was
effective in the 4th h of incapacitation (35%; p < 0.05) when compared with the control group (Fig. 2C).
|
Effect of IL-4, -10, and -13 on the Hot-plate Response.
IL-4
(5 ng/cavity), IL-10 (10 ng/cavity), IL-13 (2.5 ng/cavity), or
indomethacin (2 mg/kg) administrated i.p. to mice did not alter the
reaction time during 90 min of observation. In contrast, morphine (5 mg/kg, i.p.), used as a positive control, caused a significant
elevation (up to 660%) of the reaction time of the animals during this
period (Fig. 3).
|
Effect of Pretreatment with Naloxone Upon the Antinociceptive
Activity of IL-4, -10, and -13 in Acetic Acid-Induced Writhing in
Mice.
Subcutaneous injection of naloxone 15 min before IL-4 (5 ng/cavity), IL-10 (10 ng/cavity), or IL-13 (2.5 ng/cavity) did not affect the antinociceptive activity of these cytokines in the writhing
response to acetic acid (0.1 ml/10 g body weight of a 0.6% v/v
solution) in mice. This dose of naloxone, however, blocked the
analgesic effect of morphine (5 mg/kg, i.p.; Fig.
4). In the same manner, naloxone had no
effect upon antinociceptive activity of the cytokines on articular
incapacitation induced by zymosan (data not shown).
|
Effect of IL-4, -10, and IL-13 upon TNF-
and IL-1
Production
by Peritoneal Cells Harvested from Cavities Stimulated with
Zymosan.
The peritoneal cells harvested from cavities stimulated
15 min before with zymosan (1 mg/animal) released significant amounts of TNF-
and IL-1
into the supernatant after incubation for
12 h in vitro compared with the cells harvested from cavities
injected only with saline. IL-4 (5 ng/cavity), IL-10 (10 ng/cavity), or IL-13 (2.5 ng/cavity) pretreatment caused a significant decrease of
both TNF-
(60%, p < 0.05; 53%, p < 0.05; 100%, p < 0.001, respectively) and IL-1
(80%, p < 0.05; 100%, p < 0.001;
100%, p < 0.001, respectively) release when compared
with the zymosan-only group (Fig. 5).
|
Potentiation by Antisera Against Interleukin-4, -10, or -13 of the
Nociceptive Response to Zymosan in the Writhing Test in Mice.
Antisera against IL-4, -10, and -13 (50 µl; i.p.), but not a
preimmune (control) serum (50 µl; i.p.), injected 15 min before zymosan (500 µg/0.2 ml/mouse; i.p.) potentiated the zymosan-induced nociceptive writhing response: Ab IL-4 = 63% (p < 0.05); Ab IL-10 = 95% (p < 0.01), and Ab
IL-13 = 95% (p < 0.01; Fig.
6A).
|
Potentiation by Antisera Against Interleukin-4, -10, or -13 of the Nociceptive Response to Zymosan in the Rat Knee Joint Incapacitation Test. Antisera against IL-4, -10, or -13 (50 µl i.a.), but not a preimmune (control) serum (50 µl i.a.), injected 15 min before zymosan (500 µg/25 µl/cavity; i.a.) potentiated the zymosan-induced nociception in the knee joint when compared with nontreated animals: Ab IL-4 = 181% (p < 0.05), Ab IL-10 = 222% (p < 0.05), and Ab IL-13 = 287% (p < 0.001; Fig. 6B).
| |
Discussion |
|---|
|
|
|---|
IL-4, -10, and -13 are classified as anti-inflammatory cytokines.
The principal anti-inflammatory activities of these molecules are a
consequence of their capacity to inhibit the production of
proinflammatory cytokines such as IL-1
, -6, -12, -18, TNF-
, and
chemokines (Hart et al., 1989
; De Waal Malefyt et al., 1991
; Fiorentino
et al., 1991
; Cassatella et al., 1993
; Isomaki et al., 1996
; Muchamuel
et al., 1997
). Moreover, they also inhibit the induction of the enzymes
COX-2 and iNOS, which are involved in the production of prostaglandins
and NO, respectively (Cunha et al., 1992b
; Niiro et al., 1995
; Onoe et
al., 1996
; Niiro et al., 1997
). Using a model of inflammatory
mechanical hyperalgesia (a rat paw pressure test), it was shown that
IL-4, -10, and -13 have antihyperalgesic effects. These
antihyperalgesic effects are due to inhibition of the release of
hyperalgesic cytokines and also eicosanoids, although we cannot exclude
the possibility of the involvement of other mediators (Poole et al.,
1995
; Cunha et al., 1999
; Lorenzetti et al., 2001
).
In the present study, we demonstrated that IL-4, -10, and -13 inhibited
the writhing response in mice after the intraperitoneal injection of
zymosan or acetic acid, and the knee-joint incapacitation induced by
the intra-articular injection of zymosan into the rat knee joints. The
mediators involved in the genesis of the nociception observed in the
writhing test are the eicosanoids and sympathomimetic amines, the
release of which is preceded by the release of the nociceptive
cytokines TNF-
, IL-1
, and IL-8 (Duarte et al., 1988
; Thomazzi et
al., 1997
; Ribeiro et al., 2000
). The rat knee-joint incapacitation
test was designed for the study of articular incapacitation, defined as
the inability of a rat subjected to an experimentally induced arthritis
to deambulate normally (Tonussi and Ferreira, 1992
). In this
test, articular incapacitation is assumed to be due to altered
nociception following injection of an inflammatory substance, such as
carrageenin or zymosan, into the joints (Tonussi and Ferreira, 1992
;
Rocha et al., 1999
). After zymosan injection, the animals display a
progressive articular incapacitation that begins in the 2nd h and is
maximal between the 3rd and 4th h of arthritis (Rocha et al., 1999
).
Eicosanoids and TNF-
are involved in the genesis of the knee joint
incapacitation (Tonussi and Ferreira, 1992
; Rocha et al., 1999
).
There is evidence in the literature showing that several cytokines,
including peripherally released IL-10, are able to cross the
blood-brain barrier and act on the central nervous system (Di Santo et
al., 1997
). To investigate a possible central component of IL-4, -10, and IL-13 antinociceptive effects, the hot-plate test was used.
Although morphine, used as a control, caused a significant elevation in
the test reaction time, the cytokines had no effect. There is evidence
in the literature, however, showing that IL-10 injected peripherally is
able to inhibit pain behavior following intraspinal injection of
quisqualic acid (Plunkett et al., 2001
). The use of different
experimental models could explain these apparently conflicting results.
Although we used the hot-plate test in this study, other authors have
used a model in which there is a marked expression of inflammatory
cytokines within the central nervous system (Di Santo et al., 1997
;
Plunkett et al., 2001
). In our study, IL-4, -10, and -13 seem to exert
their antinociceptive effect through a peripheral mechanism via
inhibition of the release of proinflammatory cytokines, although we
cannot exclude the interference of a centrally derived mechanism.
It is known that some cytokines can stimulate endogenous opioid release
(Czlonkowski et al., 1993
). In this context, we found that IL-4, -10, and -13 differed from morphine in that their antinociceptive actions
were not reversed by pretreatment with naloxone (an opioid antagonist),
suggesting that endogenous opioids probably are not involved in the
analgesic effect of these cytokines.
Recently, we have demonstrated that the writhing response induced by
zymosan and acetic acid in mice is dependent on the presence of
resident peritoneal macrophages and mast cells and the consequent release of IL-1
and TNF-
by these cells. It was shown that
reduction of the peritoneal macrophage or mast cell population
significantly inhibited the zymosan- or acetic acid-induced writhing
response. On the other hand, increasing the peritoneal macrophage
population caused an increase in the number of writhings induced by
both stimuli (Ribeiro et al., 2000
). It was also found that the
mediators involved in the abdominal writhing test are multiple and
include sympathomimetic amines and eicosanoids. Previous data from our group have shown that the release of these pronociceptive substances is
preceded by the release of the proinflammatory cytokines IL-1, TNF, and
IL-8 in zymosan and acetic acid induced writhes (Duarte et al., 1988
;
Thomazzi et al., 1997
; Ribeiro et al., 2000
). In the present study, we
demonstrated that intraperitoneal administration of IL-4, -10, or -13 inhibited the release of IL-1
and TNF-
by macrophages harvested
from the peritoneal cavity after zymosan injection. These molecules
also inhibit the production of eicosanoids by macrophages harvested
from peritoneal cavities of mice and stimulated by cytokines (Poole et
al., 1995
; Cunha et al., 1999
; Lorenzetti et al., 2001
). These results
suggest that the antinociceptive effects of the cytokines used in this
study are due to inhibition both of the release by resident peritoneal
cells of cytokines that mediate nociception, such as TNF-
and
IL-1
, and also the expression of COX-2 induced by these cytokines.
The potentiation of the zymosan-induced writhing response and knee
joint incapacitation by specific antibodies to IL-4, -10, and IL-13
suggests that endogenous release of these cytokines has a role in
limiting the development of the nociceptive response at least during
inflammatory pain reactions. In previous studies, we have demonstrated
that antibodies against IL-4, -10, and -13 also potentiated the
mechanical hyperalgesia induced by intraplantar injection of
carrageenin and that the potentiation was due to inhibition of the
release of inflammatory cytokines (Poole et al., 1995
; Cunha et al.,
1999
; Lorenzetti et al., 2001
).
In summary, our data provide evidence that IL-4, -10, and -13 display antinociceptive activity that is at least partially due to the inhibition of the release of the proinflammatory cytokines IL-1 and TNF. Additionally, these analgesic cytokines may exert an endogenous down-regulating effect in the release of the eicosanoids. The fact that these cytokines share a similar analgesic effect suggest that a common pathogenic pathway downstream from the receptor coupling of these cytokines may be operating. Such a mechanism could be an interesting target to develop new analgesic therapeutic options.
| |
Acknowledgments |
|---|
We are grateful for the technical assistance of Sérgio Roberto Rosa and Giuliana Bertozzi Francisco.
| |
Footnotes |
|---|
Accepted for publication September 4, 2002.
Received for publication May 14, 2002.
This work was supported by the grants from the following Brazilian Foundations: Fundação de Amparo à Pesquisa no Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Pronex), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Procad).
DOI: 10.1124/jpet.102.038703
Address correspondence to: Ronaldo Albuquerque Ribeiro, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, R. Cel. Nunes de Melo 1127, 60.430-270 Fortaleza CE, Brazil. E-mail: ribeiror{at}ufc.br
| |
Abbreviations |
|---|
TNF, tumor necrosis factor; IL, interleukin; COX, cyclooxygenase; iNOS, inducible nitric oxide synthase; S, saline; NT, nontreated; Zym, zymosan; Ab IL, antiserum against interleukin.
| |
References |
|---|
|
|
|---|
in mediating the production of IL-8 triggered by lipopolysaccharide.
J Exp Med
178:
2207-2211
in murine macrophages.
Biochem Biophys Res Commun
182:
1155-1159[CrossRef][Medline].
in the development of inflammatory hyperalgesia.
Br J Pharmacol
107:
660-664[Medline].
as a potent hyperalgesic agent antagonized by a tripeptide analogue.
Nature (Lond)
334:
698-700[CrossRef][Medline].
, interleukin-1 and prostaglandin E2.
Proc Natl Acad Sci USA
86:
3803-3807
, IFN-
and IL-2 production.
J Immunol
158:
2898-2903[Abstract].
required as a costimulatory factor for interferon gamma-induced activation.
Proc Natl Acad Sci USA
89:
8676-8680
and IL-4.
J Immunol
152:
2060-2065[Abstract].This article has been cited by other articles:
![]() |
W. A. Verri Jr., A. T. G. Guerrero, S. Y. Fukada, D. A. Valerio, T. M. Cunha, D. Xu, S. H. Ferreira, F. Y. Liew, and F. Q. Cunha IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice PNAS, February 19, 2008; 105(7): 2723 - 2728. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. I. Svensson, M. Zattoni, and C. N. Serhan Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing J. Exp. Med., February 19, 2007; 204(2): 245 - 252. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||